What are the effects of semaglutide on the body?

What does semaglutide do to appetite and hunger signals?

The clearest effect most people notice is that hunger simply quiets down. Semaglutide binds to GLP-1 receptors in the hypothalamus (the part of the brain that regulates appetite) and in doing so reduces the urgency of hunger between meals. Food cravings, particularly for high-fat and high-sugar options, tend to soften. People often describe eating half a plate and feeling genuinely done, rather than forcing themselves to stop.

This isn't the appetite suppression of willpower. It's a pharmacological shift in the signals your body sends. The STEP 1 trial, published in the New England Journal of Medicine, documented an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose — driven substantially by this reduction in energy intake, not just calorie-counting.

GLP-1 receptors are also present in the gut and liver, which is why semaglutide's effects on the body extend well beyond what happens in the brain. Appetite is the most felt change, but it's one piece of a wider picture. For more on the broader pharmacological profile, our semaglutide overview covers the mechanism in detail.

How does semaglutide affect digestion and the gut?

Gastric emptying (the rate at which food moves from your stomach into the small intestine) slows measurably on semaglutide. This is deliberate. Food sitting longer in the stomach prolongs the feeling of fullness, which reduces the drive to eat again soon after a meal. In practical terms: a lunch that once left you hungry by 3pm might now carry you comfortably to dinner.

The digestive effects are also why gastrointestinal side effects are the most commonly reported. Nausea, loose stools, constipation, burping and indigestion all appear in the trial data and on the NHS medicines page for semaglutide. These tend to be most pronounced when starting treatment or moving up a dose, then settle for most people within a week or two. Staying well-hydrated and eating smaller, lower-fat meals helps the adjustment considerably.

A smaller number of people experience more persistent GI symptoms. If side effects are severe or don't ease, that's a conversation for your prescriber, not something to manage alone. Our page on unwanted semaglutide effects goes through the full safety picture, including the rarer ones worth knowing about.

One practical note: keeping your pen in the fridge door (2–8°C, alongside everyday items) makes the weekly injection easy to slot into a routine, but always check the patient information leaflet for the exact storage window that applies to your product.

What changes happen to body weight over time, and how quickly?

Weight loss on semaglutide is gradual and cumulative. The titration schedule (moving up from 0.25mg through several dose steps to the 2.4mg maintenance level, roughly every four weeks) means the body adapts progressively. Most people begin to notice the effects on appetite and food intake within the first two to four weeks, though visible weight change takes longer. Clinical trials measured their primary outcomes at 68 weeks, which reflects the reality that meaningful fat loss is a months-long process.

The STEP 1 data recorded an average of around 15% body-weight reduction at 2.4mg. A newer higher dose, 7.2mg, was approved by the MHRA in April 2026 and early trial data suggest average losses approaching those seen with tirzepatide. For a fuller comparison of the two medicines, our Wegovy treatment page covers both dose schedules and what the head-to-head evidence currently shows.

Weight loss slows or plateaus if treatment stops, semaglutide's effects on the body are sustained only while the medicine is active. That's not a flaw; it reflects how the underlying biology works. Thinking of it as an ongoing tool, rather than a course with a finish line, helps set realistic expectations from the start. For a sense of when early changes typically appear, our guide to when semaglutide effects are usually felt covers the typical timeline week by week.

Are there effects beyond weight, cardiovascular, liver, or other?

Yes, and this is an area where the science is developing quickly. Semaglutide holds a UK licence not only for weight management but also for reducing the risk of major cardiovascular events in eligible adults with obesity or overweight and established cardiovascular disease. In July 2026, the MHRA granted conditional approval for semaglutide (Wegovy) to treat MASH (a form of fatty liver disease) marking the first time a GLP-1 medicine has been licensed for a liver condition in the UK.

These indications reflect a growing body of evidence that GLP-1 receptor activation has effects on the body reaching beyond appetite and body weight: reduced inflammation, improved insulin sensitivity, and direct effects on cardiovascular and hepatic tissue. Research is ongoing, and these are emerging areas rather than settled medicine.

At nume, our prescribers focus on the licensed weight-management indication; cardiovascular and liver conditions require specialist clinical oversight. If you're considering treatment and want to understand how semaglutide might interact with other medicines you take (antihistamines, for instance) our semaglutide and antihistamine page addresses that specific question. And if you're comparing Wegovy with other treatment options, our weight-loss treatments overview sets out what's currently licensed in the UK and how the options differ.

Pricing is a common practical question at this stage. Our Wegovy cost guide explains what private treatment typically involves and what a legitimate price should include. When you're ready to take the next step, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered clinician, not a decision tree.